These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 20718496

  • 21. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
    Debnath AK, Radigan L, Jiang S.
    J Med Chem; 1999 Aug 26; 42(17):3203-9. PubMed ID: 10464007
    [Abstract] [Full Text] [Related]

  • 22. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ, Hristova K, Pujol M, Gómara MJ, Haro I, Alsina MA, Busquets MA.
    J Colloid Interface Sci; 2011 Aug 01; 360(1):124-31. PubMed ID: 21565353
    [Abstract] [Full Text] [Related]

  • 23. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
    Shi W, Cai L, Lu L, Wang C, Wang K, Xu L, Zhang S, Han H, Jiang X, Zheng B, Jiang S, Liu K.
    Chem Commun (Camb); 2012 Dec 07; 48(94):11579-81. PubMed ID: 23093045
    [Abstract] [Full Text] [Related]

  • 24. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
    Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.
    Biochim Biophys Acta; 2016 Jun 07; 1860(6):1139-48. PubMed ID: 26905802
    [Abstract] [Full Text] [Related]

  • 25. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R, Vasconcelos A, Pérez Y, Cruz A, Pujol M, Alsina MA, Gómara MJ, Haro I.
    Eur J Med Chem; 2014 Oct 30; 86():589-604. PubMed ID: 25218908
    [Abstract] [Full Text] [Related]

  • 26. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
    Gómara MJ, Haro I.
    Curr Med Chem; 2014 Apr 30; 21(10):1188-200. PubMed ID: 23931277
    [Abstract] [Full Text] [Related]

  • 27. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
    Lee MK, Kim HK, Lee TY, Hahm KS, Kim KL.
    Exp Mol Med; 2006 Feb 28; 38(1):18-26. PubMed ID: 16520549
    [Abstract] [Full Text] [Related]

  • 28. Computational identification of self-inhibitory peptides from envelope proteins.
    Xu Y, Rahman NA, Othman R, Hu P, Huang M.
    Proteins; 2012 Aug 28; 80(9):2154-68. PubMed ID: 22544824
    [Abstract] [Full Text] [Related]

  • 29. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.
    Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.
    J Virol; 2011 Jul 28; 85(14):7037-47. PubMed ID: 21543477
    [Abstract] [Full Text] [Related]

  • 30. HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.
    Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.
    Curr Med Chem; 2014 Jul 28; 21(2):238-50. PubMed ID: 24083612
    [Abstract] [Full Text] [Related]

  • 31. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
    Domènech O, Ortiz A, Pujol M, Haro I, Muñoz M, Alsina MA, Prat J, Busquets MA, Girona V.
    Biochim Biophys Acta; 2014 May 28; 1838(5):1274-80. PubMed ID: 24530897
    [Abstract] [Full Text] [Related]

  • 32. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I, Gómara MJ, Galatola R, Domènech O, Prat J, Girona V, Busquets MA.
    Biochim Biophys Acta; 2011 Jun 28; 1808(6):1567-73. PubMed ID: 21377446
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.
    McLinden JH, Stapleton JT, Klinzman D, Murthy KK, Chang Q, Kaufman TM, Bhattarai N, Xiang J.
    J Gen Virol; 2013 Apr 28; 94(Pt 4):774-782. PubMed ID: 23288422
    [Abstract] [Full Text] [Related]

  • 35. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
    Labrosse B, Labernardière JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F.
    J Virol; 2003 Jan 28; 77(2):1610-3. PubMed ID: 12502877
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediator.
    Tsvetkov VB, Serbin AV.
    J Comput Aided Mol Des; 2014 Jun 28; 28(6):647-73. PubMed ID: 24862639
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.